Skip to main content
. Author manuscript; available in PMC: 2014 Oct 1.
Published in final edited form as: Curr Oncol Rep. 2013 Oct;15(5):500–508. doi: 10.1007/s11912-013-0337-1

Fig. 1.

Fig. 1

Therapeutic targets for immunoregulatory antibodies. GITR glucocorticoid-induced tumor necrosis factor receptor related protein, NK cell natural killer cell, KIR killer inhibitory receptor, LAG-3 lymphocyte activation gene 3, TIM-3 T-cell immunoglobulin- and mucin-domain containing 3, CTLA-4 cytotoxic T lymphocyte antigen 4, BTLA B- and T-cell attenuator; PD-1 programmed cell death 1, PD-L1 programmed cell death 1 ligand 1